These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 15102572)

  • 1. Nesiritide for the treatment of congestive heart failure.
    Iyengar S; Feldman DS; Trupp R; Abraham WT
    Expert Opin Pharmacother; 2004 Apr; 5(4):901-7. PubMed ID: 15102572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nesiritide: a review of its use in acute decompensated heart failure.
    Keating GM; Goa KL
    Drugs; 2003; 63(1):47-70. PubMed ID: 12487622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of nesiritide in patients with acute decompensated heart failure.
    DeWald TA; Hernandez AF
    Expert Rev Cardiovasc Ther; 2010 Feb; 8(2):159-69. PubMed ID: 20136602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of nesiritide for the treatment of decompensated heart failure.
    Emerman CL
    Rev Cardiovasc Med; 2002; 3 Suppl 4():S28-34. PubMed ID: 12439428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practical application of human B-type natriuretic peptide as a therapeutic intervention in the perioperative setting.
    Feldman DS; Sun B
    Heart Fail Rev; 2004 Jul; 9(3):203-8. PubMed ID: 15809818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nesiritide: a novel approach for acute heart failure.
    Vichiendilokkul A; Tran A; Racine E
    Ann Pharmacother; 2003 Feb; 37(2):247-58. PubMed ID: 12549957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials.
    Sackner-Bernstein JD; Kowalski M; Fox M; Aaronson K
    JAMA; 2005 Apr; 293(15):1900-5. PubMed ID: 15840865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of nesiritide (human b-type natriuretic peptide) and dobutamine on heart rate variability in decompensated heart failure.
    Aronson D; Burger AJ
    Am Heart J; 2004 Nov; 148(5):e16. PubMed ID: 15523294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natriuretic peptides for the treatment of acute heart failure: a focus on nesiritide in recent clinical trials.
    Fajardo J; Heywood JT; Patterson JH; Adams K; Chow SL
    Expert Rev Cardiovasc Ther; 2015; 13(7):743-51. PubMed ID: 26028173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of nesiritide and predictors of urine output in acute decompensated heart failure: results from ASCEND-HF (acute study of clinical effectiveness of nesiritide and decompensated heart failure).
    Gottlieb SS; Stebbins A; Voors AA; Hasselblad V; Ezekowitz JA; Califf RM; O'Connor CM; Starling RC; Hernandez AF
    J Am Coll Cardiol; 2013 Sep; 62(13):1177-83. PubMed ID: 23747790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and hemodynamic effects of nesiritide (B-type natriuretic peptide) in patients with decompensated heart failure receiving beta blockers.
    Abraham WT; Cheng ML; Smoluk G;
    Congest Heart Fail; 2005; 11(2):59-64. PubMed ID: 15860969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nesiritide: harmful or harmless?
    Dorsch MP; Rodgers JE
    Pharmacotherapy; 2006 Oct; 26(10):1465-78. PubMed ID: 16999657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nesiritide (Natrecor): a new treatment for acutely decompensated congestive heart failure.
    Colbert K; Greene MH
    Crit Care Nurs Q; 2003; 26(1):40-4. PubMed ID: 12669946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nesiritide: a new drug for the treatment of decompensated heart failure.
    Elkayam U; Akhter MW; Tummala P; Khan S; Singh H
    J Cardiovasc Pharmacol Ther; 2002 Jul; 7(3):181-94. PubMed ID: 12232567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study.
    Burger AJ; Horton DP; LeJemtel T; Ghali JK; Torre G; Dennish G; Koren M; Dinerman J; Silver M; Cheng ML; Elkayam U;
    Am Heart J; 2002 Dec; 144(6):1102-8. PubMed ID: 12486437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nesiritide for the treatment of decompensated heart failure.
    Wylie JV; Tsao L
    Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):803-13. PubMed ID: 15500426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Nesiritide in heart failure: commercial success or therapeutic advance?].
    Stampfli T; Perrier A
    Rev Med Suisse; 2006 Jan; 2(50):295-8. PubMed ID: 16503047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nesiritide: a new therapy for the treatment of heart failure.
    Maisel AS
    Cardiovasc Toxicol; 2003; 3(1):37-42. PubMed ID: 12668889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine.
    Wang DJ; Dowling TC; Meadows D; Ayala T; Marshall J; Minshall S; Greenberg N; Thattassery E; Fisher ML; Rao K; Gottlieb SS
    Circulation; 2004 Sep; 110(12):1620-5. PubMed ID: 15337695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nesiritide: the latest drug for treating heart failure.
    Fontana D
    Crit Care Nurse; 2006 Feb; 26(1):39-44, 46-7. PubMed ID: 16443809
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.